{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:40:37Z","timestamp":1770763237018,"version":"3.50.0"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T00:00:00Z","timestamp":1440374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"LEO Pharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Actinic keratoses (<jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>s) are precursors to invasive squamous cell carcinoma and can progress if untreated. Limited data support the use of ingenol mebutate to treat <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>s on more than one area of the body simultaneously.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate safety, efficacy and treatment satisfaction when treating separate areas simultaneously or sequentially with different concentrations of ingenol mebutate gel.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this phase <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>b study (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>01787383), patients with clinically visible, non\u2010hyperkeratotic <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>s on two separate treatment areas (face\/scalp and trunk\/extremities) were randomized to simultaneous or sequential treatment with ingenol mebutate gel (0.015% and 0.05%). Endpoints included composite local skin response (<jats:styled-content style=\"fixed-case\">LSR<\/jats:styled-content>) score 3\u00a0days after first application, complete <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> clearance and percentage reduction in <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>s at week 8.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were no statistically significant differences between simultaneous (<jats:italic>n<\/jats:italic>\u00a0=\u00a0101) and sequential (<jats:italic>n<\/jats:italic>\u00a0=\u00a098) groups in composite <jats:styled-content style=\"fixed-case\">LSR<\/jats:styled-content> score (10.4 vs. 9.7), complete clearance (52.7% vs. 46.9%) or percentage reduction in <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>s (83.4% vs. 79.1%). Mean composite <jats:styled-content style=\"fixed-case\">LSR<\/jats:styled-content> scores on face\/scalp and trunk\/extremities were similar for both groups. Adverse event (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>) incidence was comparable between groups, the most common treatment\u2010related <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s being pruritus and pain at the application site.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Treating <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>s with ingenol mebutate simultaneously or sequentially gave similar results in terms of tolerability (<jats:styled-content style=\"fixed-case\">LSR<\/jats:styled-content> score, <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) and efficacy (complete clearance). Therefore, the physician and patient can select the most convenient treatment regimen, with confidence in achieving a similar outcome.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.13211","type":"journal-article","created":{"date-parts":[[2015,8,24]],"date-time":"2015-08-24T10:38:09Z","timestamp":1440412689000},"page":"2192-2198","source":"Crossref","is-referenced-by-count":16,"title":["A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body"],"prefix":"10.1111","volume":"29","author":[{"given":"G.","family":"Pellacani","sequence":"first","affiliation":[{"name":"Department of Dermatology University of Modena and Reggio Emilia Modena Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Peris","sequence":"additional","affiliation":[{"name":"Department of Dermatology Catholic University of Rome Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Guillen","sequence":"additional","affiliation":[{"name":"Department of Dermatology Instituto Valenciano de Oncolog\u00eda Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Clonier","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S Ballerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Larsson","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S Ballerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Venkata","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S Ballerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Puig","sequence":"additional","affiliation":[{"name":"Melanoma Unit Dermatology Department Hospital Clinic of Barcelona University of Barcelona &amp; CIBERER Instituto de Slud Carlos III Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,24]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1727","article-title":"A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications","volume":"63","author":"Braakhuis BJ","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.14025"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.05.013"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.048"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0366-077X.2003.05621.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.052"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24284"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00185-8"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08268.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12420"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.09.053"},{"key":"e_1_2_6_13_1","first-page":"651","article-title":"Development of a treatment algorithm for actinic keratoses: a European Consensus","volume":"18","author":"Stockfleth E","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_14_1","first-page":"741","article-title":"Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12\u2010month results","volume":"13","author":"Berman B","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08271.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.001"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.134"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-012-0015-9"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.535"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019907"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91658-3"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.6.722"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111170"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2766"},{"key":"e_1_2_6_25_1","first-page":"19","article-title":"Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100\u00a0cm2 on the forearm(s) of patients with actinic keratosis","volume":"7","author":"Anderson L","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-014-0059-9"},{"key":"e_1_2_6_28_1","first-page":"35","article-title":"Non\u2010adherence to topical treatments for actinic keratosis","volume":"8","author":"Shergill B","year":"2013","journal-title":"Patient Prefer Adherence"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13211","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.13211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T12:44:41Z","timestamp":1695559481000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,24]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/jdv.13211"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13211","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,24]]}}}